Cyteir Therapeutics (United States)

Novel irreversible covalent BTK inhibitors discovered using DNA-encoded chemistry

John P. Guilinger, Archna Archna, Martin Augustin et al. · Bioorganic & Medicinal Chemistry · 2021 · 48 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Genetic and Small Molecule Disruption of the AID/RAD51 Axis Similarly Protects Nonobese Diabetic Mice from Type 1 Diabetes through Expansion of Regulatory B Lymphocytes

Jeremy Ratiu, Jeremy J. Racine, Muneer G. Hasham et al. · The Journal of Immunology · 2017 · 38 citations · Full text

Life Sciences, Genetics, Immunology +17

Enhancing the efficacy of glycolytic blockade in cancer cells<i>via</i>RAD51 inhibition

John J. Wilson, Kin-Hoe Chow, Nathan J. Labrie et al. · Cancer Biology & Therapy · 2018 · 27 citations · Full text

Medicine, Cancer Biology, Oncology +16

First-in-human phase I/II study of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination in patients with advanced solid and hematologic cancers.

Ryan C. Lynch, Johanna C. Bendell, Ranjana H. Advani et al. · Journal of Clinical Oncology · 2021 · 23 citations

Medicine, Oncology, Pharmacology +15

Phase 1 results of a phase 1/2 trial of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination, in patients with advanced solid and hematologic cancers.

Ryan C. Lynch, Pamela N. Münster, Ranjana H. Advani et al. · Journal of Clinical Oncology · 2022 · 10 citations

Medicine, Oncology, Pharmacology +16